cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.8031970
title: Parcel2D Real - A real-world image dataset of cuboid-shaped parcels with 2D and 3D annotations

description: Real-world dataset of ~400 images of cuboid-shaped parcels with full 2D and 3D annotations in the COCO format. Relevant computer vision tasks: bounding box detection instance segmentation keypoint estimation 3D bounding box estimation 3D voxel reconstruction (.binvox files) 3D reconstruction (.obj files) For details, see our paper and project page. If you use this resource for scientific research, please consider citing <pre><code>@inproceedings{naumannScrapeCutPasteLearn2022, title = {Scrape, Cut, Paste and Learn: Automated Dataset Generation Applied to Parcel Logistics}, author = {Naumann, Alexander and Hertlein, Felix and Zhou, Benchun and Dörr, Laura and Furmans, Kai}, booktitle = {{{IEEE Conference}} on {{Machine Learning}} and Applications ({{ICMLA}})}, date = 2022 }</code></pre>
DOI: 10.6084/m9.figshare.23680881
title: Pre and post disaster model for a flood event: Rio Tula, Hidalgo State, Mexico

description: In the first spreadsheet distances in kilometers are shown of the possible shelters to the the municipal presidencies (town halsl) that can serve as collection and distribution centers. Distances are in kilometers and were obtained from google maps. In the second spreadsheet, the upper table shows the solution that uses the original demand, showing people who will be evacuated from the municipal presidencies to the shelters. Both the demand of each region is considered such as the capacity of the shelters and the distance to each of them. Not all shelters were used. The Table below shows the time in hours required to evacuate if 5, 10, 15 and 20 vans are assigned to each municipal presidency, with a capacity of 15 passengers each; in addition to the vans required to evacuate in 3, 5 or 8 hours. <br> In the third spreadsheet, the upper table shows the solution that uses the demand decreased in 10%, showing people who will be evacuated from the municipal presidencies to the shelters. In the fourth spreadsheet, the upper table shows the solution that uses the demand increased in 10%, showing people who will be evacuated from the municipal presidencies to the shelters. <br>
DOI: 10.25345/c5rn30j44
title: MassIVE MSV000092434 - Autophagy collaborates with apoptosis pathways to control oligodendrocyte number
title: The samples are in vitro cultured oligodendrocyte precursor cells in differentiation medium for 3 days. There are 2 groups: D3HET (ATG5F/+ CNP-Cre, TMT channels 126, 127, 128) and D3KO (ATG5F/F; CNP-Cre, TMT channels 129, 130, 131), with each group comprising 3 biological replicates. Subsequently, all the samples were lysed and subjected to TMT (Tandem Mass Tag) labeling, high pH fractionation into 8 fractions (F1-F8).
DOI: 10.5519/qd.onqe0gqy
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (1 records)
DOI: 10.25345/c5mw28r00
title: MassIVE MSV000092435 - GNPS - Staining of human teeth &gt; 800 samples
title: This dataset contains LC-MS/MS data from &gt; 800 samples with different staining of human teeth
DOI: 10.5281/zenodo.8144596
title: Data for "Chasing rainbows and ocean glints: Inner working angle constraints for the Habitable Worlds Observatory"

description: Data for the paper on "Chasing rainbows and ocean glints: Inner working angle constraints for the Habitable Worlds Observatory"
DOI: 10.5281/zenodo.8144595
title: Data for "Chasing rainbows and ocean glints: Inner working angle constraints for the Habitable Worlds Observatory"

description: Data for the paper on "Chasing rainbows and ocean glints: Inner working angle constraints for the Habitable Worlds Observatory"
DOI: 10.6084/m9.figshare.22245907
title: Asthma outcomes in pediatric patients with 30-day follow-up after an asthma hospitalization in a Medicaid-managed care program

description: National asthma guidelines recommend an outpatient follow-up after hospitalization for asthma. Our aim is determine if a follow-up visit within 30 days after an asthma hospitalization impacts risk for re-hospitalization and emergency department visits for asthma within the following year. This was a retrospective cohort study of claims data of Texas Children’s Health Plan (a Medicaid managed care program) members age 1 to &lt;18 years and hospitalized for asthma between January 1, 2012, and December 31, 2018. Primary outcomes were days to re-hospitalization and emergency department visit between 30 days and 365 days following the index hospitalization. We identified 1,485 children age 1 to &lt;18 years hospitalized for asthma. Comparing those with a 30 day follow-up to those without, there was no difference in days to re-hospitalization (adjusted hazard ratio 1.23, 95% Confidence Interval (CI) 0.74–2.06) or emergency department visit for asthma (aHR 1.08, 95% CI 0.88–1.33). Inhaled corticosteroid and short acting beta agonist dispensing were greater in the group completing the 30 day follow-up (means of 2.8 and 4.8 respectively for those with follow-up, 1.6 and 3.5 respectively for those without, <i>p</i> &lt; 0.0001). Having a follow-up outpatient visit within 30 days of an asthma hospitalization is not associated with a decrease in asthma re-hospitalization or emergency department visit in the 30–365 day period following the index hospitalization. Non-adherence to regular use of inhaled corticosteroid medication was high in both groups. These findings suggest need for improvement in the quality and quantity of post hospital asthma follow-up.
DOI: 10.6084/m9.figshare.22674985
title: Impact of multimorbidity patterns in hospital admissions: the case study of asthma

description: <b>Background:</b> Most previous studies assessing multimorbidity in asthma assessed the frequency of individual comorbid diseases. <b>Objective:</b> We aimed to assess the frequency and clinical and economic impact of co-occurring groups of comorbidities (comorbidity patterns using the Charlson Comorbidity Index) on asthma hospitalizations. <b>Methods:</b> We assessed the dataset containing a registration of all Portuguese hospitalizations between 2011–2015. We applied three different approaches (regression models, association rule mining, and decision trees) to assess both the frequency and impact of comorbidities patterns in the length-of-stay, in-hospital mortality and hospital charges. For each approach, separate analyses were performed for episodes with asthma as main and as secondary diagnosis. Separate analyses were performed by participants’ age group. <b>Results:</b> We assessed 198340 hospitalizations in patients &gt;18 years old. Both in hospitalizations with asthma as main or secondary diagnosis, combinations of diseases involving cancer, metastasis, cerebrovascular disease, hemiplegia/paraplegia, and liver disease displayed a relevant clinical and economic burden. In hospitalizations having asthma as a secondary diagnosis, we identified several comorbidity patterns involving asthma and associated with increased length-of-stay (average impact of 1.3 [95%CI=0.6–2.0]–3.2 [95%CI=1.8-4.6] additional days), in-hospital mortality (OR range=1.4 [95%CI=1.0–2.0]–7.9 [95%CI=2.6–23.5]) and hospital charges (average additional charges of 351.0 [95%CI=219.1–482.8] to 1470.8 [95%CI=1004.6–1937.0]) Euro compared with hospitalizations without any registered Charlson comorbidity). Consistent results were observed with association rules mining and decision tree approaches. <b>Conclusions:</b> Our findings highlight the importance not only of a complete assessment of patients with asthma, but also of considering the presence of asthma in patients admitted by other diseases, as it may have a relevant impact on clinical and health services outcomes.
DOI: 10.6084/m9.figshare.22881278
title: Open-inhaler versus single-inhaler triple therapy (long-acting muscarinic antagonist, inhaled corticosteroid, and long-acting β<sub>2</sub>-agonist) in asthma patients: a narrative review

description: To review the evidence for the use of open-inhaler (inhaled corticosteroid [ICS] plus long-acting β<sub>2</sub>-agonist [LABA] with separate add-on long-acting muscarinic antagonist [LAMA]) versus single-inhaler triple therapy (ICS/LABA/LAMA combination) and the merits of add-on LAMA to ICS/LABA in patients with uncontrolled asthma. Original research articles were identified from PubMed using the search term “triple therapy asthma.” Information was also retrieved from the ClinicalTrials.gov website. Articles detailing the use of add-on LAMA to ICS plus LABA (open-inhaler triple therapy), and closed triple therapy compared with ICS plus LABA dual therapy, addressing patient symptoms, exacerbations, and health-related quality of life. Open-inhaler triple therapy was associated with a significantly reduced incidence of hospitalizations and emergency department visits and a decrease in ICS dose, oral corticosteroids use, and antibiotics use. Exacerbations and acute respiratory events were also reduced. Single-inhaler triple therapy showed a greater improvement in lung function, asthma control, and health status and was noninferior to open-inhaler triple therapy for Asthma Quality of Life Questionnaire scores. Single-inhaler triple therapy may also lead to improved therapy adherence. Add-on LAMA to ICS plus LABA (open- or single-inhaler triple therapy) improves the response in patients who remain symptomatic and provides a reasonable alternative to ICS dose escalation in treatment-refractory patients.
DOI: 10.6084/m9.figshare.22881278.v1
title: Open-inhaler versus single-inhaler triple therapy (long-acting muscarinic antagonist, inhaled corticosteroid, and long-acting β<sub>2</sub>-agonist) in asthma patients: a narrative review

description: To review the evidence for the use of open-inhaler (inhaled corticosteroid [ICS] plus long-acting β<sub>2</sub>-agonist [LABA] with separate add-on long-acting muscarinic antagonist [LAMA]) versus single-inhaler triple therapy (ICS/LABA/LAMA combination) and the merits of add-on LAMA to ICS/LABA in patients with uncontrolled asthma. Original research articles were identified from PubMed using the search term “triple therapy asthma.” Information was also retrieved from the ClinicalTrials.gov website. Articles detailing the use of add-on LAMA to ICS plus LABA (open-inhaler triple therapy), and closed triple therapy compared with ICS plus LABA dual therapy, addressing patient symptoms, exacerbations, and health-related quality of life. Open-inhaler triple therapy was associated with a significantly reduced incidence of hospitalizations and emergency department visits and a decrease in ICS dose, oral corticosteroids use, and antibiotics use. Exacerbations and acute respiratory events were also reduced. Single-inhaler triple therapy showed a greater improvement in lung function, asthma control, and health status and was noninferior to open-inhaler triple therapy for Asthma Quality of Life Questionnaire scores. Single-inhaler triple therapy may also lead to improved therapy adherence. Add-on LAMA to ICS plus LABA (open- or single-inhaler triple therapy) improves the response in patients who remain symptomatic and provides a reasonable alternative to ICS dose escalation in treatment-refractory patients.
DOI: 10.6084/m9.figshare.23268880
title: Dupilumab long-term efficacy in patients with non–OCS–dependent asthma with and without evidence of allergic asthma

description: The open-label extension TRAVERSE study (NCT02134028) assessed dupilumab long-term safety and efficacy in patients who completed Phase 2/3 dupilumab asthma studies. This post hoc analysis evaluated long-term efficacy in type 2 patients with and without evidence of allergic asthma who enrolled in TRAVERSE from Phase 3 QUEST (NCT02414854) and Phase 2b (NCT01854047) studies. Non–type 2 patients with evidence of allergic asthma were also assessed. Unadjusted annualized exacerbation rates during parent study and TRAVERSE treatment period, and changes from parent study baseline in pre-bronchodilator forced expiratory volume in 1 s (FEV<sub>1</sub>) and in 5-item Asthma Control Questionnaire (ACQ-5) scores were assessed in patients from QUEST and Phase 2b; change from parent study baseline in total IgE level was assessed in patients enrolled from Phase 2b. 2062 patients from Phase 2b and QUEST enrolled in TRAVERSE. Of these, 969 were type 2 with evidence of allergic asthma; 710 were type 2 without evidence of allergic asthma; and 194 were non–type 2 with evidence of allergic asthma at parent study baseline. In these populations, reductions in exacerbation rates observed during parent studies were sustained during TRAVERSE. Type 2 patients who switched from placebo arm to dupilumab in TRAVERSE experienced similar reductions in severe exacerbation rates, and improvements in lung function and asthma control to those patients who already received dupilumab during the parent study. Dupilumab efficacy was sustained for up to 3 years in patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma, with or without evidence of allergic asthma. ClinicalTrials.gov identifier: NCT02134028
DOI: 10.6084/m9.figshare.23268880.v1
title: Dupilumab long-term efficacy in patients with non–OCS–dependent asthma with and without evidence of allergic asthma

description: The open-label extension TRAVERSE study (NCT02134028) assessed dupilumab long-term safety and efficacy in patients who completed Phase 2/3 dupilumab asthma studies. This post hoc analysis evaluated long-term efficacy in type 2 patients with and without evidence of allergic asthma who enrolled in TRAVERSE from Phase 3 QUEST (NCT02414854) and Phase 2b (NCT01854047) studies. Non–type 2 patients with evidence of allergic asthma were also assessed. Unadjusted annualized exacerbation rates during parent study and TRAVERSE treatment period, and changes from parent study baseline in pre-bronchodilator forced expiratory volume in 1 s (FEV<sub>1</sub>) and in 5-item Asthma Control Questionnaire (ACQ-5) scores were assessed in patients from QUEST and Phase 2b; change from parent study baseline in total IgE level was assessed in patients enrolled from Phase 2b. 2062 patients from Phase 2b and QUEST enrolled in TRAVERSE. Of these, 969 were type 2 with evidence of allergic asthma; 710 were type 2 without evidence of allergic asthma; and 194 were non–type 2 with evidence of allergic asthma at parent study baseline. In these populations, reductions in exacerbation rates observed during parent studies were sustained during TRAVERSE. Type 2 patients who switched from placebo arm to dupilumab in TRAVERSE experienced similar reductions in severe exacerbation rates, and improvements in lung function and asthma control to those patients who already received dupilumab during the parent study. Dupilumab efficacy was sustained for up to 3 years in patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma, with or without evidence of allergic asthma. ClinicalTrials.gov identifier: NCT02134028
DOI: 10.6084/m9.figshare.22245907.v3
title: Asthma outcomes in pediatric patients with 30-day follow-up after an asthma hospitalization in a Medicaid-managed care program

description: National asthma guidelines recommend an outpatient follow-up after hospitalization for asthma. Our aim is determine if a follow-up visit within 30 days after an asthma hospitalization impacts risk for re-hospitalization and emergency department visits for asthma within the following year. This was a retrospective cohort study of claims data of Texas Children’s Health Plan (a Medicaid managed care program) members age 1 to &lt;18 years and hospitalized for asthma between January 1, 2012, and December 31, 2018. Primary outcomes were days to re-hospitalization and emergency department visit between 30 days and 365 days following the index hospitalization. We identified 1,485 children age 1 to &lt;18 years hospitalized for asthma. Comparing those with a 30 day follow-up to those without, there was no difference in days to re-hospitalization (adjusted hazard ratio 1.23, 95% Confidence Interval (CI) 0.74–2.06) or emergency department visit for asthma (aHR 1.08, 95% CI 0.88–1.33). Inhaled corticosteroid and short acting beta agonist dispensing were greater in the group completing the 30 day follow-up (means of 2.8 and 4.8 respectively for those with follow-up, 1.6 and 3.5 respectively for those without, <i>p</i> &lt; 0.0001). Having a follow-up outpatient visit within 30 days of an asthma hospitalization is not associated with a decrease in asthma re-hospitalization or emergency department visit in the 30–365 day period following the index hospitalization. Non-adherence to regular use of inhaled corticosteroid medication was high in both groups. These findings suggest need for improvement in the quality and quantity of post hospital asthma follow-up.
DOI: 10.6084/m9.figshare.22674985.v1
title: Impact of multimorbidity patterns in hospital admissions: the case study of asthma

description: <b>Background:</b> Most previous studies assessing multimorbidity in asthma assessed the frequency of individual comorbid diseases. <b>Objective:</b> We aimed to assess the frequency and clinical and economic impact of co-occurring groups of comorbidities (comorbidity patterns using the Charlson Comorbidity Index) on asthma hospitalizations. <b>Methods:</b> We assessed the dataset containing a registration of all Portuguese hospitalizations between 2011–2015. We applied three different approaches (regression models, association rule mining, and decision trees) to assess both the frequency and impact of comorbidities patterns in the length-of-stay, in-hospital mortality and hospital charges. For each approach, separate analyses were performed for episodes with asthma as main and as secondary diagnosis. Separate analyses were performed by participants’ age group. <b>Results:</b> We assessed 198340 hospitalizations in patients &gt;18 years old. Both in hospitalizations with asthma as main or secondary diagnosis, combinations of diseases involving cancer, metastasis, cerebrovascular disease, hemiplegia/paraplegia, and liver disease displayed a relevant clinical and economic burden. In hospitalizations having asthma as a secondary diagnosis, we identified several comorbidity patterns involving asthma and associated with increased length-of-stay (average impact of 1.3 [95%CI=0.6–2.0]–3.2 [95%CI=1.8-4.6] additional days), in-hospital mortality (OR range=1.4 [95%CI=1.0–2.0]–7.9 [95%CI=2.6–23.5]) and hospital charges (average additional charges of 351.0 [95%CI=219.1–482.8] to 1470.8 [95%CI=1004.6–1937.0]) Euro compared with hospitalizations without any registered Charlson comorbidity). Consistent results were observed with association rules mining and decision tree approaches. <b>Conclusions:</b> Our findings highlight the importance not only of a complete assessment of patients with asthma, but also of considering the presence of asthma in patients admitted by other diseases, as it may have a relevant impact on clinical and health services outcomes.
DOI: 10.25345/c5h41jx6j
title: MassIVE MSV000092436 - mTor Neonatal Heart Regeneration
title: Global proteomics data captured from P8 hearts, 7 days post-MI or sham surgery. Hearts were treated at 4, 5, and 6 days post surgery with saline or rapamycin.
DOI: 10.6084/m9.figshare.23680974
title: Punishment credibility and cooperation in public good games

description: Dataset from a public good experiment with punishment opportunities. It consists of three treatment conditions that vary the probability with which punishment decisions are carried out (p). The treatment variable takes "P100" (p=1), "P80" (p=0.8), and "P20" (p=0.2). The dataset records contribution decisions, punishment decisions, first-stage and final-period payoffs, and socioeconomic variables extracted from subjects.
DOI: 10.6084/m9.figshare.23680974.v1
title: Punishment credibility and cooperation in public good games

description: Dataset from a public good experiment with punishment opportunities. It consists of three treatment conditions that vary the probability with which punishment decisions are carried out (p). The treatment variable takes "P100" (p=1), "P80" (p=0.8), and "P20" (p=0.2). The dataset records contribution decisions, punishment decisions, first-stage and final-period payoffs, and socioeconomic variables extracted from subjects.
DOI: 10.25345/c5cc0v41b
title: MassIVE MSV000092437 - FI-MS Dataset, E. coli TS mutants
title: Flow injection analysis dataset of temperature-sensitive E. coli mutants.
DOI: 10.6073/pasta/f89874c9c42517fd9dec64e703b460f1
title: Silver film response to sulfate reduction activity in alpine and subalpine wetlands, 2022.

description: Alpine ecosystems serve as crucial water resources for many areas of the world, and biogeochemical cycling in these regions can influence the chemistry of water flowing into downslope watersheds. Alpine and subalpine wetlands are understudied systems of particular interest since lowland wetlands are known to have high rates of biogeochemical activity that can disproportionally affect carbon (C) and nutrient uptake, sequestration, and transformations within the landscape. Wetland processes play a central role in sulfur (S) transformations and have conditions that can support sulfate reduction. Sulfate reduction determines the sequestration of S in wetlands and interacts closely with a multitude of other element cycles, including iron, carbon, nitrogen, and mercury. Previous work in Niwot alpine and subalpine wetlands noted large variability in sulfate reduction rates within wetland soils. Samples taken less than a meter away from each other sometimes showed almost 70x higher or lower rates (Rea, unpublished work). This work sought to adapt a silver film method to quantify sulfate reduction rates over small-scale spatial areas. The method proved valuable as a quick indicator of sulfate reduction activity and was able to visualize soil heterogeneity. However, the silver films were not sensitive enough to quantify sulfate reduction rates in situ.
DOI: 10.5517/ccdc.csd.cc2f53tk
title: CCDC 2239248: Experimental Crystal Structure Determination

description: Related Article: Misaki Nakagawa, Shinpei Kusaka, Atsushi Kiyose, Toshinobu Nakajo, Hiroaki Iguchi, Motohiro Mizuno, Ryotaro Matsuda|2023|J.Am.Chem.Soc.|145|12059|doi:10.1021/jacs.3c01225
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2f53vl
title: CCDC 2239249: Experimental Crystal Structure Determination

description: Related Article: Misaki Nakagawa, Shinpei Kusaka, Atsushi Kiyose, Toshinobu Nakajo, Hiroaki Iguchi, Motohiro Mizuno, Ryotaro Matsuda|2023|J.Am.Chem.Soc.|145|12059|doi:10.1021/jacs.3c01225
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2f53wm
title: CCDC 2239250: Experimental Crystal Structure Determination

description: Related Article: Misaki Nakagawa, Shinpei Kusaka, Atsushi Kiyose, Toshinobu Nakajo, Hiroaki Iguchi, Motohiro Mizuno, Ryotaro Matsuda|2023|J.Am.Chem.Soc.|145|12059|doi:10.1021/jacs.3c01225
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.